<--- Back to Details
| First Page | Document Content | |
|---|---|---|
 Date: 2012-02-29 07:00:03Pharmacology Pharmaceutical Management Agency Dabigatran Pharmaceutical industry Warfarin Anticoagulant Direct thrombin inhibitor Alternative medicine Pharmacy Chemistry Pharmaceutical sciences Organic chemistry |
Add to Reading List |
Pharmaceutical Management Agency Annual Review 2011 Highlights | warfarin isotype genetic, warfarin first affects which factor new alternative for warfarin warfarin and coagulation pathway. warfarin substitutes provac warfarin 24 mg. validated methods for warfarin sodium medical warfaDocID: 1pADC - View Document |
| Pharmaceutical Management Agency Annual Review 2011 HighlightsDocID: 18xrA - View Document |
| Use of 4-factor prothrombin complex concentrate in the treatment of a gastrointestinal hemorrhage complicated by dabigatranDocID: 15XFC - View Document |
| Treatment injury case study October 2012 – Issue 49 Sharing information to enhance patient safety Dabigatran usageDocID: 14Wt0 - View Document |
| Guideline for managing patients on Dabigatran (Pradaxa®) StatewideDocID: 14V05 - View Document |